Market Newsdesk

November 17, 2020 10:33 am

OptimizeRx and Questex’s Fierce Life Sciences Tackle Industry’s Top Challenges in Design Thinking Event, Innovate4Outcomes

Event Brings Providers and Life Sciences Leaders Together to Collaborate on Solutions for Better Patient Outcomes

ROCHESTER, Mich., Nov. 17, 2020 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, has partnered with information services provider, Fierce Life Sciences, to develop a collaborative, design thinking event to tackle some of the biggest challenges facing healthcare.

The event will bring together some of the industry’s most prominent thought leaders to innovate solutions for new and traditional healthcare challenges.

The onset of COVID-19 in the first quarter of 2020 forced everyone to adapt to a rapid expansion of digital healthcare options and the new widespread challenge of delayed treatments. With this event, OptimizeRx, in partnership with Fierce Life Sciences, offers a unique opportunity for participants to collaborate with thought leaders and brainstorm solutions to the following challenges:

As face-to-face interactions remain off the table until at least the middle of 2021, what more can be done to virtually support providers in delivering appropriate care?
What role can clinicians play in directing digital strategies that encourage patients to follow recommended courses of treatment and achieve positive outcomes?
Patient support programs are largely unadopted, but providers report that they can successfully promote patient outcomes. What can be done to further empower patients to utilize support programs?
Social media can have a huge impact on patients. How can social media and other channels be harnessed to shape authentic engagement experiences for patients and improve health outcomes?

“As we continue to navigate the lasting impact of COVID-19 on our healthcare infrastructure, we believe it is essential that we continually collaborate and partner with leading experts in life sciences and care delivery,” commented Steve Silvestro, chief commercial officer at OptimizeRx. “These partnerships and collaborations help ensure that we are not only supporting but cultivating innovation. We are thrilled to bring together these excellent thought leaders for this event, where we can collaborate on actionable solutions that address the real-world problems faced today by providers and patients.”

Innovate4Outcomes team leads include:

Ray Gomez – Director of Worldwide Omni-Channel Content and Channel Strategy, BD

Hiyam Nadel RN, MBA, CCG – Director of the Center for Innovations in Care Delivery, Massachusetts General Hospital

Neal Wolff – Vice President, Marketing, Nevakar , Inc.

Ritesh Patel – Chief Digital Officer, Ogilvy Health

Angelo Campano – SVP, Principal, Agency Channels, OptimizeRx

Steve Silvestro – Chief Commercial Officer, OptimizeRx.

See full list of team leads here.

Innovate4Outcomes
Virtual Event

Date: Thursday, December 3, 2020
Time: 2:00 pm – 4:00 p.m. EST.

Attendance will be
limited to
100 participants.

About
Questex

Questex helps people live better and longer. Questex brings people together in the markets that help people live better: travel, hospitality and wellness; the industries that help people live longer: life science and healthcare; and the technologies that enable and fuel these new experiences. We live in the experience economy – connecting our ecosystem through live events, surrounded by data insights and digital communities. We deliver experience and real results. It happens here. For more information, visit questex.com.

About OptimizeRx

OptimizeRx is a digital health company that provides communications solutions for life science companies, physicians and patients. Connecting over half of healthcare providers in the U.S. and millions of patients through a proprietary network, the OptimizeRx digital health platform helps patients afford and stay on medications. The platform unlocks new patient and physician touchpoints for life science companies along the patient journey, from point-of-care, to retail pharmacy, through mobile patient engagement.

For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com.

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

OptimizeRx Contact
Doug Baker, CFO
Tel (248) 651-6568 (x807)
[email protected]

Media Relations Contact
Maira Alejandra, Media Relations Manager
Tel (754) 245-7070
[email protected]

Investor Relations Contact
Ron Both, CMA
Tel (949) 432-7557
[email protected]

November 17, 2020 10:29 am

Pressure BioSciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update

Instrument Sales Increase 68%, Total Revenue Increases 7%, Operating Loss Decreases 23% (Q/Q); Planned Release of Revolutionary UST System in Mid-2021 Expected to Drive Major Revenue Growth and Progression to Profitability

Investor Conference Call Scheduled for Tuesday, November 17, 2020 at 4:30 PM EST

PR Newswire

SOUTH EASTON, Mass., Nov. 17, 2020 /PRNewswire/ — Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, services, and platform solutions to the worldwide life sciences and other industries, today announced financial results for the third quarter ended September 30, 2020, provided a business update, and offered limited guidance for FY2021.

Mr. Richard T. Schumacher, President and CEO of PBI, commented: “We are delighted with the results of the third quarter 2020, particularly in the measurable progress made in three important areas: (i) key operational and technical projects (see highlight bullets below); (ii) revenue increases in our products and services offerings; and (iii) important restructuring improvements in the reduction of onerous, variable-rate convertible debt. As previously reported, the Company’s first and second quarter 2020 results were substantially impacted by business interruptions and/or distractions for PBI clients and prospects. However, third quarter 2020 results demonstrated a dramatic recovery, with Q3 total revenue exceeding the revenue of Q1 and Q2 2020 combined and topping all previous quarterly revenue results since Q4 2018. Similarly, instrument sales in Q3 2020 exceeded instrument sales in Q1 and Q2 2020 combined, and contracted services revenue for our Ultra Shear Technology™ (“UST™”) nanoemulsions and BaroFold™ biopharmaceutical protein refolding and recovery platforms in Q3 2020 also exceeded revenue for the same services in Q1 and Q2 2020 combined.”

Mr. Schumacher continued: “We have been especially proud of our strong progress in the restructuring and reduction of onerous, variable-rate convertible debt and the consequential improvement in our investment grade profile. On December 31, 2019 we carried approximately $5.4 million of very expensive, variable-rate convertible debt on our books. We successfully reduced this onerous debt to approximately $1.7 million by Sept 30, 2020 through a combination of cash and conversion into PBIO common stock at a value of $2.50/share. We also carried about $1.1M in merchant cash advances (“MCAs”) on December 31, 2019; MCA balances were reduced to $0 by September 30, 2020, primarily through a combination of cash, conversion of debt into stock at a value of $2.50/share, and warrant awards with a $3.50 exercise price. Cash for the debt paydowns and restructurings above was sourced from friendly, long-term investors who we anticipate, based on past performance, will likely convert their safer, less onerous fixed-rate loans into equity in the near future.”

Recent Operational and Technical Highlights

Launch of our Revolutionary UST-Based System to Make High Quality, Stable, Water-Soluble Nanoemulsions

On target to launch our unique BaroShear K45 Nanoemulsification System by mid-2021
Novel, proprietary system designed to revolutionize the processing of immiscible liquids (like oils in water) into water-soluble, long-term stable, highly absorbable, innately bioavailable nanoemulsions
Resulting formulations could potentially have enormous success in many very large and rapidly growing markets, including high-value pharmaceuticals, cosmetics, nutraceuticals (such as CBD-infused products), liquid foods and beverages, as well as industrial products including inks, paints and lubricants
Announced receipt of purchase orders for twelve (12) BaroShear K45 nanoemulsification systems being manufactured for mid-2021 release
Completed build-out of our GMP-compliant manufacturing laboratory, an application development showcase for the BaroShear K45 and our industrial scale, high volume (2 liters/minute) UST-based nanoemulsification systems

Expansion of our Recently Launched BaroFold Contract Services Business

We entered into ongoing service agreements with two biopharma companies seeking to determine if our patented BaroFold platform could significantly impact and improve the quality of their early-stage protein therapeutics
We began discussions with potential CRO and CMO partners for the expansion of our BaroFold services
We continued to expand the PBIO contract services laboratory with additional specialized equipment and new methods/applications

Intellectual Property (Patents)

We were awarded the first U.S. patent for our revolutionary Ultra Shear Technology Platform.
We were awarded a pivotal U.S. patent for our best-selling, pressure-based consumable device, the PCT MicroPestle

Collaborations

We signed a worldwide, co-marketing alliance with Leica Microsystems (a Danaher company), integrating PBI’s Pressure Cycling Technology (“PCT”) with their laser microdissection platform, prior to mass spec analyses. Leica and PBI believe that the combination of their proprietary technology platforms provides the potential to accelerate cancer R&D with an innovative and proprietary tumor processing workflow
Earlier this year, PBI and RedShiftBio demonstrated the potential of combining their proprietary technologies to enable a new tool for the development and production of biotherapeutics

Financial Results: Q3 2020 vs. Q3 2019 (rounded to nearest hundred except earnings per share)

Products and services revenues were $534,000 for the 2020 third quarter compared to $501,000 for the same quarter of 2019, a 7% increase. This increase was primarily attributable to increased sales of instruments, which totaled $312,700 in Q3 2020 compared to $185,800 in Q3 2019, an increase of 68%. Revenue from consumable products was $49,000 for the third quarter of 2020 compared to $112,000 for the same period in 2019, a 56% decrease. Contracted scientific services for BaroFold protein refolding applications and UST services provided revenue of $84,200 in Q3 2020, compared to $149,200 in Q3 2019, a decrease of 44%. These decreases in consumable product sales and scientific services were primarily attributable to the negative impact that the COVID-19 pandemic had on the operations of many of our customers.

Operating loss for Q3 2020 was $819,000 compared to $1,069,000 for the same period in 2019, a decrease in operating loss of 23%. This decrease was primarily due to lower investor relations services, stock-based compensation expenses, personnel costs, and marketing expenditures.

Loss per common share – basic and diluted– was $(1.02) for Q3 2020 compared to loss per common share of $(2.20) for the same period in 2019.

PBI’s Chairman of the Board, Mr. Jeffrey N. Peterson, offered an overview perspective: “The excitement of our early vision for PBI was based upon the anticipated broad potential of multiple, patented high-pressure technology platforms, now spanning the PCT platform for sample preparation, the BaroFold platform for protein refolding/recovery of biotherapeutics, and the UST platform for processing a new generation of extremely effective nanoemulsions. These unique and proprietary pressure-based platforms address numerous and diverse large market opportunities worldwide. The Company has successfully developed and poised these technologies for market readiness, rapid revenue growth, and a path to major revenue growth and profitability in 2021. We believe that the restructuring of PBI’s debt, already alleviating much of our onerous variable-rate convertible debt exposure, has dramatically repositioned the Company for new investment to eliminate the remaining onerous variable-rate debt, fund our UST platform inventory build for the twelve pre-orders already received for the new BaroShear K45 nanoemulsification system, and drive our conversion to profitability by late 2021.”

Earnings Call

The Company will hold an Earnings Conference Call at 4:30 PM EDT on Tuesday, November 17, 2020. To attend this teleconference via telephone, Dial-in: (877) 407-8033 (North America), (201) 689-8033 (International). Verbal Passcode: PBIO Third Quarter 2020 Financial Results Call. Replay Number (877) 481-4010 (North America), (919) 882-2331 (International); Replay ID Number: 38901. Teleconference Replay Available for 30 days.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” estimates,” “predicts,” “projects,” “potential” or “continue” or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. The Company’s financial results for the three months ended September 30, 2020 may not necessarily be indicative of future results. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. Due to rounding, numbers presented throughout this and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS
UNAUDITED
	For the Three Months Ended September 30,
	2020		2019
Revenue:
Products, services, other	$	533,862	$	501,158
Total revenue		533,862		501,158

Costs and expenses:
Cost of products and services		247,013		285,794
Research and development		247,432		276,712
Selling and marketing		173,372		133,032
General and administrative		684,807		874,611
Total operating costs and expenses		1,352,624		1,570,149

Operating loss		(818,762)		(1,068,991)

Other (expense) income:
Interest expense, net		(2,204,593)		(2,124,477)
Unrealized gain on investment in equity securities		140,461		–
Loss on extinguishment of liabilities		(395,854)		(185,203)
Other income		–		4,674
Total other expense		(2,459,986)		(2,305,006)
Income tax benefit				217,168
Net loss		(3,278,748)		(3,156,829)
Deemed dividend on beneficial conversion feature		–		(675,979)
Preferred stock dividends		(396,970)		(492,494)
Net loss attributable to common stockholders	$	(3,675,718)	$	(4,325,302)
Basic and diluted net loss per share attributable to common stockholders	$	(1.02)	$	(2.20)

Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation		3,612,958		1,967,872

PRESSURE BIOSCIENCES, INC. AND SUBSIDIARY
CONSOLIDATED BALANCE SHEETS
Unaudited
	September 30, 2020		December 31, 2019
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	94,752	$	29,625
Accounts receivable		330,459		229,402
Inventories, net of $342,496 reserve at September 30, 2020 and December 31, 2019		516,205		617,716
Loan receivable		801,250		–
Prepaid expenses and other current assets		159,739		213,549
Total current assets		1,902,405		1,090,292
Investment in equity securities		503,366		16,643
Property and equipment, net		18,733		55,590
Right of use asset leases		20,958		76,586
Intangible assets, net		512,019		576,923
TOTAL ASSETS	$	2,957,481	$	1,816,034

LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable	$	706,319	$	815,764
Accrued employee compensation		450,591		451,200
Accrued professional fees and other		2,035,252		1,658,452
Accrued interest		5,593,508		2,949,621
Deferred revenue		47,623		23,248
Operating lease liability		20,958		76,586
Convertible debt, net of unamortized discounts of $4,738,724 and $619,227, respectively		7,095,113		6,121,338
Other debt, net of unamortized discounts of $0 and $1,769, respectively		886,501		1,675,667
Other related party debt		105,000		81,500
Total current liabilities		16,940,865		13,853,376
LONG TERM LIABILITIES
Long term debt		527,039		–
Deferred revenue		25,957		18,065
TOTAL LIABILITIES		17,493,861		13,871,441
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT
Series D Convertible Preferred Stock, $.01 par value; 850 shares authorized; 300 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively (Liquidation value of $300,000)		3		3
Series G Convertible Preferred Stock, $.01 par value; 240,000 shares authorized; 80,570 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		806		806
Series H Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 10,000 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		100		100
Series H2 Convertible Preferred Stock, $.01 par value; 21 shares authorized; 21 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		–		–
Series J Convertible Preferred Stock, $.01 par value; 6,250 shares authorized; 3,458 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		35		35
Series K Convertible Preferred Stock, $.01 par value; 15,000 shares authorized; 6,880 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		68		68
Series AA Convertible Preferred Stock, $.01 par value; 10,000 shares authorized; 7,983 and 7,939 shares issued and outstanding on September 30, 2020 and December 31, 2019, respectively		80		80
Common stock, $.01 par value; 100,000,000 shares authorized; 3,839,256 and 2,549,620 shares issued and outstanding on September 30, 2020 and December 31, 2019 respectively		38,392		25,496
Warrants to acquire common stock		28,207,172		22,599,177
Additional paid-in capital		49,079,182		44,261,105
Accumulated deficit		(91,862,218)		(78,942,277)
Total stockholders’ deficit		(14,536,380)		(12,055,407)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	2,957,481	$	1,816,034

Investor Contacts:

Richard T. Schumacher, President and CEO (508) 230-1828 (T)
Jeffrey N. Peterson, Chairman of the Board (650) 812-8121 (T)

View original content:http://www.prnewswire.com/news-releases/pressure-biosciences-inc-reports-third-quarter-2020-financial-results-and-provides-business-update-301175002.html

SOURCE Pressure BioSciences, Inc.

November 17, 2020 10:29 am

Nuance Awarded Frost & Sullivan’s 2020 Global Company of the Year Award for Leading the Conversational AI Market

Nuance’s future-proof innovations are aimed at reducing clinician burnout and ensuring accurate as well as complete clinical documentation

PR Newswire

LONDON, Nov. 17, 2020 /PRNewswire/ — Based on its recent analysis of the global market for AI-powered solutions enabling patient safety in healthcare, Frost & Sullivan recognizes Nuance Communications with the 2020 Global Company of the Year Award. A pioneer in conversational AI and ambient clinical intelligence, the company has designed innovative AI solutions that document physician-patient conversations, securely operating across physical and virtual clinical settings.

A pioneer and leading market player in conversational AI, Nuance offers digital intelligence to assist daily clinical work and life. Its speech recognition, clinical documentation, and transcription solutions for the healthcare industry are used by more than 550,000 physicians and 10,000 healthcare organizations for providing unmatched clinical, financial, and patient engagement outcomes. Its flagship solution, Nuance Dragon® Medical One, is a revolutionary cloud-based application offered on a Software-as-a-Service (SaaS) model and hosted on the Microsoft Azure cloud.

“Addressing the looming issue of clinician burnout arising from the heavy clinical documentation workload, Dragon Medical One stores and communicates more than 300 million patient stories, annually,” said Suchismita Das, Industry Analyst. “Continual updates to the speech recognition technology improve the solution’s capability significantly, thereby reducing medication errors and ensuring patient safety through improved quality of care. Nuance also pioneered another important advancement by enabling cloud-support through Nuance Dragon Medical One, envisioning a future delivery model that involves care teams spread across various locations.”

Nuance is a frontrunner in introducing solutions that align with healthcare megatrends, such as the shift towards value-based healthcare and greater automation to reduce or eliminate manual data input errors. It has brought to the market several innovative, next-generation patient safety solutions through strategic partnerships. A recent and major strategic activity was the integration of Nuance’s Dragon Ambient eXperience (DAX) and Microsoft Teams. This AI-powered ambient clinical intelligence speeds up telehealth workflow solutions adoption, thus reducing clinician burnout with clinical documentation that writes itself. Other significant partnerships are with Cerner to reduce the physician’s cognitive burden at the point-of-care through Nuance’s virtual assistant platform, as well as the integration of Nuance’s AI-powered virtual assistant platform with the Epic EHR.

“It is noteworthy that Nuance created DAX to improve both the physician and patient experience,” noted Das. “Overall, strategic partnerships, technological enhancements of solutions to improve quality of care, and increased focus on ambient clinical intelligence and digital assistants underpin Nuance’s market leadership.”

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:
Kristen Moore
P: 210.247.3823
E: [email protected]

About Nuance Communications

Nuance Communications (NASDAQ: NUAN) is a technology pioneer with market leadership in conversational AI and ambient intelligence. A full-service partner trusted by 90 percent of US hospitals and 85 percent of the Fortune 100 companies worldwide, Nuance creates intuitive solutions that amplify people’s ability to help others.

Contact:
Nancy Scott
P: 781.565.4130
E: [email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/nuance-awarded-frost–sullivans-2020-global-company-of-the-year-award-for-leading-the-conversational-ai-market-301175003.html

SOURCE Frost & Sullivan

November 17, 2020 10:20 am

Nu Skin Celebrates 700 Million Meals Donated To Malnourished Children Around The World

More than 120,000 children are being fed each day through the company’s Nourish the Children initiative with the goal to feed more

PR Newswire

PROVO, Utah, Nov. 17, 2020 /PRNewswire/ — Nu Skin today announced it has surpassed 700 million meals purchased and donated since 2002 through its Nourish the Children (NTC) initiative. Malnourished children in more than 60 countries around the world have been fed VitaMeal, a nutrient-dense food, from one of NTC’s third-party charity partners after Nu Skin sales leaders, customers and employees purchase and donate the bag of food.

“Thank you to the generosity of our sales leaders, customers and employees who support the Nourish the Children initiative and make it possible for us to feed more than 120,000 children every day,” said Steven J. Lund, Nu Skin chairman of the board. “I continue to be amazed at how the Nu Skin family comes together to be a force for good throughout the world, helping those in need. We realize that much more still needs to be done to combat malnutrition, and it’s our desire to grow this program to benefit even more children.”

Recently the company started rolling out enhancements to the Nourish the Children program to encourage even greater participation. A 10-meal bag is now available in some markets, and the company has added a $1 donation to the Nu Skin Force for Good Foundation for each 10-meal bag and a $2 donation for each 30-meal bag. These modifications make program participation more accessible and increase the impact we can have on malnourished children.

About VitaMeal
Unlike simple grains with a mostly caloric benefit, VitaMeal is a nutrient-dense food scientifically formulated to meet the nutritional needs of malnourished children. As part of the overall development of VitaMeal, Nu Skin’s nutritional scientists determined the ingredients and ratios that were well suited for a malnourished child. The result is a product that provides the essential vitamins and minerals, with a balance of carbohydrates, protein, fat and fiber.

About Nourish the Children
In 2002, Nu Skin took action to address the tragedy of childhood hunger and malnutrition with the development of the Nourish the Children initiative. The program begins with a highly nutritious food known as VitaMeal, developed by Nu Skin’s nutritional scientists. The company’s sales leaders, customers and employees can purchase VitaMeal and then choose to keep it or donate the food to a third-party nonprofit organization that specializes in distributing relief to those suffering from malnutrition and famine.

About Nu Skin
Founded more than 35 years ago, Nu Skin develops and distributes innovative consumer products, offering a comprehensive line of premium-quality beauty and wellness solutions. The company builds upon its scientific expertise in both skin care and nutrition to continually develop innovative product brands that include the Nu Skin® personal care brand, the Pharmanex® nutrition brand, and most recently, the ageLOC® anti-aging brand. The ageLOC brand has generated a loyal following for such products as the ageLOC LumiSpa skin cleansing and treatment device, ageLOC Youth nutritional supplement, the ageLOC Me® customized skin care system, as well as the ageLOC TR90® weight management and body shaping system. Nu Skin sells its products through a global network of sales leaders in Asia, the Americas, Europe, Africa and the Pacific. As a long-standing member of direct selling associations globally, Nu Skin is committed to the industry’s consumer guidelines that protect and support those who sell and purchase its products through the direct selling channel. Nu Skin International is a wholly owned subsidiary of Nu Skin Enterprises, Inc., which is traded on the New York Stock Exchange. More information is available at nuskin.com.

* The price of VitaMeal includes the cost of manufacturing, general overhead, distribution and sales. As is the case with other Nu Skin products, distributors are paid commissions and Nu Skin earns a profit margin from each sale of VitaMeal.

Follow Nu Skin’s Force for Good Efforts:

fb.com/forceforgood twitter.com/forceforgood

View original content to download multimedia:http://www.prnewswire.com/news-releases/nu-skin-celebrates-700-million-meals-donated-to-malnourished-children-around-the-world-301174991.html

SOURCE Nu Skin

November 17, 2020 10:18 am

Basware Introduces Spend Insights Dashboard to Provide Visual, Single View of Entire Spend & Cost-Cutting Recommendations

Basware Introduces Spend Insights Dashboard to Provide Visual, Single View of Entire Spend & Cost-Cutting Recommendations

Data Includes Direct, Indirect, PO & Non-PO Spend

ESPOO, Finland–(BUSINESS WIRE)–Basware (Nasdaq: BAS1V) has launched two enhancements to its Analytics solution: a new, highly visual Spend Insights dashboard and a new functionality to enable payment performance analysis. The Spend Insights dashboard provides a single view across an organization’s entire spend – direct, indirect, PO and non-PO – and recommendations on suggested actions, all designed to help procurement departments rapidly identify areas for potential savings. The payment performance feature now includes payment status and related details enabling the finance department to work with suppliers to improve data quality and the invoice submission process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005927/en/

Transparency is top of mind for the C-suite. Leverage automation to gain 100% spend visibility. (Graphic: Basware & Harvard Business Review Analytic Services)

“Spend consolidation has become one of the most important strategies for organizations given the recent widespread financial uncertainties,” states Sami Peltonen, VP of Purchase to Pay Product Management, Basware. “However, before cutting unnecessary costs, organizations are keen to understand exactly wherethey are spending their money. And that’s where the Spend Insights Dashboard comes into play – Spend insights is built on the backbone of Basware’s ability to capture 100% of an organization’s invoices to provide 100% spend visibility and enable what we call ‘Visible Commerce.’ The dashboard is revolutionary as it provides this complete visibility in an automated manner, allowing organizations to make more effective, data-backed decisions.”

The Spend Insights dashboard presents the data in a new, simplified user interface that enables a logical flow to an organization’s data story; it provides granular details, such as visibility into authorized and contract-based spend, in very few clicks. In addition to facilitating a more intuitive spend analysis experience, the dashboard introduces dynamic, data-driven recommendations. It not only highlights an organization’s top spend drivers, but also offers recommendations on what actions they can take to optimize their supplier base and minimize risk. By providing easy-to-consume insights on-the-go, this dashboard makes the task of understanding spend much less cumbersome.

To learn more, read New Basware Analytics dashboard provides revolutionary 100% spend visibility on the blog.

About Basware:

Basware is the only procure-to-pay and e-invoicing solution provider that empowers businesses with 100% spend visibility through 100% supplier connectivity and 100% data capture. Our cloud-based technology enables organizations to fully manage their spend, mitigate financial risk and reduce the cost of operations via automation. With the world’s largest open business network and an open technology ecosystem, we are uniquely positioned to deliver the solution required for Visible Commerce, which provides customers with complete transparency into all the flows of money, goods, and services around the world. A global company, Basware has offices in 14 countries and is traded on the Helsinki exchange (BAS1V: HE).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005927/en/

Jeanne Bernish

[email protected]

KEYWORDS: Europe Finland United States North America North Carolina

INDUSTRY KEYWORDS: Professional Services Data Management Technology Software Banking Accounting

MEDIA:

Logo

Photo

Transparency is top of mind for the C-suite. Leverage automation to gain 100% spend visibility. (Graphic: Basware & Harvard Business Review Analytic Services)

Posted on November 17, 2020 10:18 am
Life Extension® Launches New Hydrolyzed Collagen Supplement: Collagen Peptides for Skin and Joints:

Beautiful News for Your Skin, Joints and Beyond

Fort Lauderdale, FL, Nov. 17, 2020 (GLOBE NEWSWIRE) — We’ve all heard of collagen. It’s the main structural protein in your body. In fact, about one third of the total amount of protein in your body is collagen. But collagen production decreases as we age—one of the reasons for wrinkles, aging joints and other signs of aging.

To help make up for this age-related collagen loss, Life Extension^® has created Collagen Peptides for Skin and Joints: a convenient daily collagen supplement that mixes easily with water or your favorite nutritious drink! So what makes this collagen supplement stand out from all the others?

“Our collagen supplement consists of collagen types I, II and III,” said Dr. Michael Smith, Life Extension’s Director of Education. “Furthermore, the collagen in our formula is hydrolyzed. Basically, the collagen in our formula has been broken down into smaller pieces called collagen peptides.”

According to Dr. Smith, dietary collagen is a large molecule. “This makes it difficult to digest and absorb. But collagen peptides are made up of microscopic ‘bits’ of collagen that can pass through your digestive system without having to be broken down further,” said Smith. “Collagen peptides have virtually the same amount of amino acids that a fully formed, complete collagen molecule would have. Your body then uses those amino acids to re-create collagen it can use.”

So what can your body use this easily absorbable collagen for? Joints and connective tissue, for starters. “Hydrolyzed collagen can help promote joint comfort,” said Smith. “In a randomized study, 250 people reported that taking hydrolyzed collagen every day supported comfort in their knees.”

Since 80% of your skin is type I collagen and that collagen is used to make elastin, a protein that gives your skin its flexibility, it makes sense that collagen can help keep you aging beautifully. “A double-blind study found that women ages 35 to 55 had significantly improved skin elasticity after eight weeks of hydrolyzed collagen—especially compared to placebo,” Dr. Smith said.

Collagen Peptides for Skin and Joints is gluten free and Non-GMO. And because it was formulated to be tasteless, it blends nicely with anything from water to your favorite nutritious smoothie. For more information, visit LifeExtension.com/CollagenPeptides

About Life Extension^®

For 40 years, Life Extension has pursued innovative advances in health, conducting rigorous clinical trials and setting some of the most demanding standards in the industry to offer a full range of quality vitamins and nutritional supplements and blood-testing services. Life Extension’s Wellness Specialists provide personalized counsel to help customers choose the right products for optimal health, nutrition and personal care. To learn more, visit LifeExtension.com.

These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure, or prevent any disease
.

Attachments

02408A

Vert_Tag__NoReg_CMYK

Rey Searles Life Extension 954-766-8433 [email protected]

Posted on November 17, 2020 10:17 am
Automotive-Compliant Synchronous Buck Converters from Diodes Incorporated Feature Innovative Noise Reduction and Power Good Indicator

Automotive-Compliant Synchronous Buck Converters from Diodes Incorporated Feature Innovative Noise Reduction and Power Good Indicator

PLANO, Texas–(BUSINESS WIRE)–
Diodes Incorporated (Nasdaq: DIOD) has announced two highly integrated synchronous buck converters that simplify circuit design in automotive power systems with its Power Good output and its innovative EMI mitigation for noise-sensitive applications.

The AP63356Q and AP63357Q are 3.5A converters with an input voltage range of 3.8V to 32V. Leveraging peak current mode control as well as high-side and low-side power MOSFETs on-chip, the converters minimize external components to reduce bill of materials (BOM) costs and board size.

Both devices have a Power Good indicator with an internal 5MΩ pull-up resistor useful for power sequencing. To further aid sequencing, their enable pin has accurate voltage thresholds, which allows adjustment of the input voltage device power-on and undervoltage lockout (UVLO). The high-voltage capability of the EN pin allows direct connection to VIN to simplify the auto-start of the device. When disabled, the converter draws only 0.6µA shutdown current typical.

Their proprietary gate-driver scheme ensures clean switching transitions while preventing switch-node ringing to minimize high-frequency radiated noise. Frequency spread spectrum (FSS) contributes further to quiet performance by dispersing switching-noise energy.

The AP63356Q operates continuously in PWM mode at the nominal 450kHz switching frequency for all loads. The AP63357Q changes to PFM mode at light loads, keeping efficiency as high as 86% at 5mA load and drawing quiescent current of just 22µA under no load.

Both devices feature low-dropout (LDO) operation, which maintains their output-voltage regulation as the input reduces to a level near the output voltage. Built-in protection features include output undervoltage protection (UVP), cycle-by-cycle peak current limit, and thermal shutdown. The protection features, along with 40V (for 400ms) input voltage surge withstand capability, enable the devices to provide a robust Automotive POL solution.

The AP63356Q and AP63357Q are qualified to AEC-Q100 Grade 1, support PPAP documentation, and are manufactured in IATF 16949 certified facilities. The devices are each available in a 3mm × 2mm V-DFN3020-13 (SWP) package with wettable flanks to aid in automated optical inspection. The unit price is $0.46 in 3000 piece quantities.

About Diodes Incorporated

Diodes Incorporated (Nasdaq: DIOD), a Standard and Poor’s SmallCap 600 and Russell 3000 Index company, delivers high-quality semiconductor products to the world’s leading companies in the consumer electronics, computing, communications, industrial, and automotive markets. We leverage our expanded product portfolio of discrete, analog, and mixed-signal products and leading-edge packaging technology to meet customers’ needs. Our broad range of application-specific solutions and solutions-focused sales, coupled with worldwide operations of 28 sites, including engineering, testing, manufacturing, and customer service, enables us to be a premier provider for high-volume, high-growth markets. For more information visit www.Diodes.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005054/en/

Company Contact:

Diodes Incorporated

Emily Yang

VP, Worldwide Sales and Marketing

P: 972-987-3900

Contact Us

Investor Relations Contact:

Shelton Group

Leanne K. Sievers

EVP, Investor Relations

P: 949-224-3874

E: [email protected]

KEYWORDS: California Texas United States North America

INDUSTRY KEYWORDS: Semiconductor Engineering Consumer Electronics Technology Manufacturing Hardware

MEDIA:

Logo

Posted on November 17, 2020 10:14 am
Pennexx Releases its Quarterly Report Showing Revenue and Talks About the Potential Value of Users

Philadelphia, PA, Nov. 17, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Pennexx has conducted an analysis that shows the potential value of gaining its first million user goal on Your Social Offers ( https://yoursocialoffers.com ).

Using figures by Forbes (https://www.forbes.com/sites/tristanlouis/2013/08/31/how-much-is-a-user-worth/?sh=4c7ab3181c51 ), a million consumer users could be estimated to value a company at $120 Million dollars.

In that article Forbes found the average user to be worth $120.84, and the average revenue per user to be $3.76. Pennexx estimates that this is an appropriate value for users that join YSO as a consumer. However, we believe YSO’s merchant users are much more valuable on an individual basis. YSO has begun its subscription service at $25 per month and believes that by offering merchants more than ten ways to grow their business, that cost is easily justified by the merchant.

Pennexx states that a higher valuation of merchant users is substantiated because merchants are readily willing to pay for client acquisition. According to https://blog.flyingsaucer.nyc/customer-acquisition-cost-by-industry, the cost for a restaurant to acquire a customer through Bing is approximately $26. Pennexx believes that it can greatly reduce client acquisition cost and therefore show a great value to the consumer.

If these forward-looking estimates hold true and Pennexx achieves a million users, this would mean a tremendous growth possible for its shareholders. We nevertheless caution the public to understand that these are forward looking statements that may not come to fruition if we do not achieve our goals of user growth.

It is because of this valuation estimation that the CEO has a strategy to keep the company as “lean and mean” as possible to keep dilution to a minimum.

Toward that goal, Pennexx has released its first quarter financial report which show its first revenue since entering into the technology sector. These earnings represent the first step of Pennexx growing its commercial viability.

This is a significant step because many companies do not transition to a sustainable revenue model and therefore cannot remain viable without significant continued investment.

Mr. Risalvato said, “I have spoken many times about the strategy of the company to grow organically as much as possible. While it is a much harder road to keep a company lean and mean, it insures the company has the least dilution of its shareholder base and is economically sound.”

He continued, “Many people have long been involved in the dream of having a successful investment in Pennexx. Some have been involved since its meat packing days. They have told me that they have confidence in me, the idea and in those involved. I appreciate that confidence greatly and hope this first step into revenue shows my commitment to this strategy.”

Mature companies in this space include; Groupon.com, Coupons.com, Rakuten, Inc.

According to Statista.com (https://www.statista.com/statistics/273226/number-of-adult-digital-coupon-users-in-the-us/ ) in 2021 there will be 145 million users using digital coupons in the United States.

Vincent said, “I believe virtually none of these estimated 140 million digital coupons are being shared on social media. We have a tremendous opportunity to do something for merchants and consumers that hasn’t been done before. ‘Redefine the distribution of coupons into social media offers shared between friends and families.’”

Pennexx also has value outside of its wholly owned subsidiary Your Social Offers ( https://yoursocialoffers.com ). Its other technologies such as its Cyber Security Dashboard, Zicix’s https://zicixgroup.com Smartphone Coupon app, Fintech Pre-Paid debit card app and Your Social Influencers program can have independent valuations, but have tremendous cross selling opportunity.

Pennexx believes its ability to ‘cross sell’ to its users offers from multiple merchants for a low cost is what distinguishes the value of its users from the typical ‘digital coupon’ or ‘digital reward or rebate’ company put valuations into accordance with the Forbes figures.

Vincent Risalvato said, “I believe Pennexx will see a tremendous growth in its user base and from this Forbes data that it can translate into the success many companies have achieved. Because of the startup stage of our company, investors getting involved today are really at the ground floor.”

For More Information

The best place to ask questions is openly on twitter @pennexx. This way they can answer them openly and publicly.

Questions may also be emailed to [email protected], many shareholders do get responses from the CEO directly when questions are emailed in. Some of them post those responses within the investor community.

It is also recommended that people follow Mr. Risalvato on Twitter at https://twitter.com/vrisalvato.

About Pennexx Foods Inc.

About Pennexx Foods Inc. (PNNX: OTCMKTS US). Pennexx, through its wholly-owned subsidiaries, is a holding company within the Software/Internet Industry focused on social media, prepaid debit cards, BitGift™, artificial intelligence, targeted marketing, and consumer rewards.

Safe Harbor Act: This release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report.

For additional information, you may also visit our website at https://yoursocialoffers.com or https://pennexx.net or call 866-928-6409. Please follow us on Twitter @Pennexx.

Posted on November 17, 2020 10:13 am
Buckle Launches New Buckle Rewards Program

Buckle Launches New Buckle Rewards Program

KEARNEY, Neb.–(BUSINESS WIRE)–
Rewards should be effortless, they’re a bright spot, a little thank you for shopping, and with that in mind The Buckle, Inc. (“Buckle”) simplified the process. Buckle’s newly updated rewards program, Buckle Rewards, launched October 19, allowing guests to earn, track, and redeem points through one platform, in real time.

There are three tiers in the program. Once a guest joins, they become a “member,” their benefits expand as they upgrade to the next tier. All Buckle Rewards members receive a $10 reward for every 300 points earned. Those who choose to become a Buckle Credit Cardholder (“Premier” and “Premier +”) earn rewards even faster, with up to three times the points depending on their tier. Buckle Credit Cardholders also have the benefit of free shipping on qualifying purchases.

“Buckle Rewards empowers the guest and truly is ‘rewards your way,’” said Cindy Casper, Director of Loyalty Programs and Sales Audit. “This program enables guests to earn, track, and redeem rewards how they want, when they want.”

As Buckle heads into the holiday season, the brand is slowing down and taking a moment to be ‘here.’ Embracing the people, places, and moments that make you realize there’s nowhere else you’d rather be. For Buckle, those people and moments revolve around the guests — which led to Buckle Rewards being crafted just for them.

About Buckle

It’s about what we like to call ‘the styled life.’ Those outfits that make you feel like the best version of yourself, that you reach for again and again. For us, it typically starts with the perfect pair of jeans. Buckle offers an unmatched selection in denim, and better denim at that. From fits, to styles, to finishes, denim is what we’re passionate about – but in more than 50 years of business, Buckle has grown to carry on-trend pieces to build an outfit from the ground, up. Each person walking into our doors has a story to tell, their own personal style, and we’re here to amplify just that. Service has always been at the heart of Buckle and continues to be as our first store in Kearney, Nebraska, has evolved into 446 stores spanning 42 states.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005362/en/

Larissa Ost, Media Relations Specialist

The Buckle, Inc.

(913) 239-1607

KEYWORDS: United States North America Nebraska

INDUSTRY KEYWORDS: Fashion Online Retail Retail Other Consumer Consumer Other Retail Department Stores

MEDIA:

Logo

Posted on November 17, 2020 10:13 am
DISYS Automation Solution Saves Healthcare Providers $1.1B Annually

D4HA™ uses automation to reduce manual labor, avoid costly errors, and increase revenue margins across the provider space

MCLEAN, Va., Nov. 17, 2020 (GLOBE NEWSWIRE) — Digital Intelligence Systems, LLC (DISYS), a global technology services firm with 10+ years of experience in the Healthcare sector, announces the launch of its new automation solution, D4HA™ for Healthcare Providers. D4HA™ is a holistic solution that is designed to reduce manual labor and improve efficiencies by leveraging the power of automation and Artificial Intelligence/Machine Learning technologies.

The healthcare industry currently lacks the ability to connect disparate data and integrate with EHR and EMR systems. This results in significant losses in revenue industry-wide, totaling $1.1B every year. 15-20% of claims are denied due to authorization issues or charge capture, while 79% of Revenue Cycle Management (RCM) platforms are using outdated technologies. These inefficiencies result in time and resource-consuming tasks that cost providers unnecessarily, as the average hospital spends about $12.1M more than it needs to on supply chain costs every year.

D4HA™ takes a proactive approach to bridging these gaps with the power of automation and AI/ML technologies. Combining intelligent front and back-end processes, autonomous AI with data analytics capabilities, and a robust framework, D4HA™ goes straight to the source of the current challenges healthcare providers are facing. D4HA™’s approach centers on developing automation solutions customized to an organization’s specific needs in three key areas:

Revenue Cycle Management;

Provider Supply Chain; and

Contact Center Operations.

The value D4HA™ delivers is clear from several clients currently leveraging it to generate more efficient outcomes in their administrative operations. One example is a leading healthcare organization who automated some of their manual RCM-Billing processes to achieve a significant ROI. This organization then set up a joint COE (Center of Excellence) on Automation to further their initiative and investment in automating several business functions to enhance outcomes and optimize cost savings going forward.

“D4HA™ meets a critical and rising need within the healthcare provider space,” said Giri Rajaiah, VP Healthcare, DISYS. “Over the past few years, providers have faced increasing revenue issues, which have been intensified recently by the COVID-19 pandemic. The new D4HA™ solution allows provider organizations to discover, deploy, and optimize automated business processes to reduce the cost of their operations and avoid revenue overruns through the power of automation. It also helps to streamline complex workflows and deliver greater efficiency at all points in their operational lifecycle.”

To learn more about D4HA™, visit https://www.disys.com/digital_health_solutions/

About Digital Intelligence Systems, LLC (DISYS)

Digital Intelligence Systems, LLC (DISYS) is a global managed services and staffing firm with 45 offices worldwide. DISYS’ vision is to be a global business partner, delivering the highest quality and most consistent services at the best value to clients worldwide. For more information about DISYS, visit www.disys.com.

MEDIA CONTACT

Sandra Schwartzman
Vice President of Public Relations
RMR & Associates
(301) 230 – 0045 x 100
[email protected]

Posts pagination

Previous page Page 1 … Page 48,016 Page 48,017 Page 48,018 … Page 48,440 Next page